Urelumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD137 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
934823-49-1  |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6502H9972N1712O2030S44 |
| Molar mass | 145.8 kg/mol |
 (what is this?) (verify) | |
Urelumab (ue rel' ue mab; also known as BMS-663513 and anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.[1]
Urelumab targets the CD137 receptor. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.[2]
A phase I clinical trial in advanced colorectal cancer and head and neck cancer is due to run until Jan 2017.[3]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.
- ↑ "Urelumab". National Cancer Institute.
- ↑ Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
This article is issued from Wikipedia - version of the 9/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.